These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

562 related items for PubMed ID: 22153888

  • 1. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ, Tucker DM.
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [Abstract] [Full Text] [Related]

  • 2. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M, Minshall ME, Pandya BJ, Baran RW, Tunis SL.
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [Abstract] [Full Text] [Related]

  • 3. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.
    Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ.
    Clin Ther; 2004 Feb; 26(2):304-21. PubMed ID: 15038953
    [Abstract] [Full Text] [Related]

  • 4. Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China.
    Gao L, Zhao FL, Li SC.
    Int J Technol Assess Health Care; 2012 Oct; 28(4):436-44. PubMed ID: 23006540
    [Abstract] [Full Text] [Related]

  • 5. Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.
    Caro JJ, Getsios D, Caro I, Klittich WS, O'Brien JA.
    Diabet Med; 2004 Nov; 21(11):1229-36. PubMed ID: 15498090
    [Abstract] [Full Text] [Related]

  • 6. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY, Ko SK, Liew D.
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [Abstract] [Full Text] [Related]

  • 7. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.
    Xie X, Vondeling H.
    Value Health; 2008 Mar; 11 Suppl 1():S23-32. PubMed ID: 18387063
    [Abstract] [Full Text] [Related]

  • 8. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA.
    Palmer AJ, Valentine WJ, Chen R, Mehin N, Gabriel S, Bregman B, Rodby RA.
    Nephrol Dial Transplant; 2008 Apr; 23(4):1216-23. PubMed ID: 18359872
    [Abstract] [Full Text] [Related]

  • 9. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.
    Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE, Diabetes Prevention Program Research Group.
    Ann Intern Med; 2005 Mar 01; 142(5):323-32. PubMed ID: 15738451
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China.
    Palmer JL, Gibbs M, Scheijbeler HW, Kotchie RW, Nielsen S, White J, Valentine WJ.
    Adv Ther; 2008 Aug 01; 25(8):752-74. PubMed ID: 18704282
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes.
    Kwon CS, Seoane-Vazquez E, Rodriguez-Monguio R.
    BMC Health Serv Res; 2018 Feb 01; 18(1):78. PubMed ID: 29391064
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
    Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, Pongcharoensuk P, Ongphiphadhanakul B, Roze S, Valentine WJ, Palmer AJ.
    Value Health; 2008 Mar 01; 11 Suppl 1():S43-51. PubMed ID: 18387067
    [Abstract] [Full Text] [Related]

  • 13. Long-term clinical and economic outcomes associated with liraglutide versus sitagliptin therapy when added to metformin in the treatment of type 2 diabetes: a CORE Diabetes Model analysis.
    Lee WC, Samyshkin Y, Langer J, Palmer JL.
    J Med Econ; 2012 Mar 01; 15 Suppl 2():28-37. PubMed ID: 22834986
    [Abstract] [Full Text] [Related]

  • 14. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C, Tentolouris N, Kourlaba G, Maniadakis N.
    Clin Drug Investig; 2016 Aug 01; 36(8):649-59. PubMed ID: 27221806
    [Abstract] [Full Text] [Related]

  • 15. A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose.
    Ramsdell JW, Grossman JA, Stephens JM, Botteman MF, Arocho R.
    Am J Manag Care; 1999 Aug 01; 5(8):1007-24. PubMed ID: 10558125
    [Abstract] [Full Text] [Related]

  • 16. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D, Calado F, Gruenberger JB, Ong SH, Carvalho D, Silva-Nunes J, Johal S, Viana R.
    J Med Econ; 2014 Jul 01; 17(7):499-507. PubMed ID: 24708176
    [Abstract] [Full Text] [Related]

  • 17. Cost saving analysis of prediabetes intervention modalities in comparison with inaction using Markov state transition model-A multiregional case study.
    Al-Omar HA, Czech M, Quang Nam T, Gottwald-Hostalek U, Vesic N, Whitehouse J, Dawson M.
    J Diabetes; 2024 May 01; 16(5):e13553. PubMed ID: 38664882
    [Abstract] [Full Text] [Related]

  • 18. The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.
    Diabetes Prevention Program Research GroupDiabetes Prevention Program Coordinating Center. dppmail@biostat.bsc.gwu.edu.
    Diabetes Care; 2012 Apr 01; 35(4):723-30. PubMed ID: 22442395
    [Abstract] [Full Text] [Related]

  • 19. [Cost-effective analysis of preventive treatment on diabetes].
    Hu Y, Chen SY, Wang JY.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 May 01; 25(5):431-4. PubMed ID: 15231174
    [Abstract] [Full Text] [Related]

  • 20. Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US.
    Tunis SL, Minshall ME.
    Curr Med Res Opin; 2010 Jan 01; 26(1):151-62. PubMed ID: 19919376
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.